Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company


Evaluate and EP Vantage Mentioned in the Press or Industry Reports

June 2018

Vertex Tops EvaluatePharma World Preview With Phase III Cystic Fibrosis Drug  - BioSpace, June 26, 2018
"In its annual list, EvaluatePharma said Vertex’s triple combination treatment VX-659, which includes tezacaftor and ivacaftor (Kalydeco), will become the most valuable project in the pharmaceutical industry pipeline” with a net present value of $13 billion."

5 Biggest Blockbuster Diabetes Drugs of the Future - TheMotleyFool, June 24, 2018
"Market research firm EvaluatePharma recently ranked what it projects will be the top diabetes drugs of 2024. Novo Nordisk's (NYSE:NVO) products dominate the list, although Eli Lilly(NYSE:LLY) and privately held Boehringer Ingelheim placed highly, as well. Here are the top five biggest blockbuster diabetes drugs of the future, according to EvaluatePharma."

Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines - Nasdaq, June 24, 2018
"EvaluatePharma recently published a list of the drugmakers with the projected highest value creation from pipeline products between 2018 and 2024."

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma  - TheStreet, June 22, 2018
"According to Evaluate Pharma, revenues derived from diabetic medications in 2016 totaled $17.4 billion for the top 10 selling drugs. Novo has three ..."

Why I'm Bullish on the Riskiest Big Biotech Stock on the Market - Nasdaq, June 21, 2018
"What's the riskiest big biotech stock on the market? According to market research firm EvaluatePharma, it's Celgene (NASDAQ: CELG)"

Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming - TheMotleyFool, June 13, 2018
"Market research firm EvaluatePharma projects that more than $250 billion in sales are at risk between 2018 and 2024 for drugs that will lose patent exclusivity."

Humira's Sales Will Decline -- and It's Fantastic News for AbbVie - TheMotleyFool, June 13, 2018
"Humira claimed a market share of 34% last year in the global anti-rheumatic products market, according to EvaluatePharma."

Roche Pulls Out An FDA Win For Venclexta, A Much Needed Win For Pipeline Expansion- Seeking Alpha, June 12, 2018
"Some analysts are expecting that this drug could earn between $1.5 to $2 billion in sales. Evaluate Pharma believes that Venclexta sales could reach as much as $3 billion by 2022."

AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024 - FiercePharma, June 7, 2018
"Even as many things change in the drug industry, at least one fact should stay the same in the coming years, according to analysts at EvaluatePharma. AbbVie's megablockbuster Humira will lead the world's drug sales charts in 2024, according to a new report, representing a record-breaking run that has lifted the company's fortunes along the way."

Second Patent Cliff Lies Ahead for Pharma With $251 Billion in Sales at Risk by 2024 - The Center for Biosimilars, June 7, 2018
"EvaluatePharma, a company that provides consensus forecasts of the pharmaceutical and biotechnology sphere, recently published the 11th edition of its World Preview."

AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024 - FiercePharma, June 7, 2018
"Even as many things change in the drug industry, at least one fact should stay the same in the coming years, according to analysts at EvaluatePharma. AbbVie's megablockbuster Humira will lead the world's drug sales charts in 2024, according to a new report, representing a record-breaking run that has lifted the company's fortunes along the way."

AdAlta courts big pharma with ‘enhanced’ anti-fibrosis drug, locks-in manufacturing agreements - Small Caps, June 5, 2018
"Meanwhile, Evaluate Pharma forecasts the market value for IPF drugs, alone, will be about US$4.2 billion by 2020."

Prescribed Reading: M&A slow ahead of BIO, ASCO - Biopharma Dive, June 1, 2018
"A recent report from Evaluate Pharma shows that oncology drugs are the top selling therapeutics on the orphan drug market. Currently, global sales of orphan drugs totaled $125 billion in 2017 and will grow to $262 billion by 2024 — cancer drugs are expected to account for 50% of that."

May 2018

Deutsche Pharmakonzerne spielen auf dem Markt für Krebsmedikamente kaum eine Rolle- Handelsblatt, May 31, 2018
"Die britische Analysefirma Evaluate Pharma etwa geht davon aus, dass er von 2016 bis 2022 um jährlich knapp 13 Prozent wächst und damit seinen Umsatz in diesem Zeitraum von 93,7 auf 192 Milliarden Dollar verdoppelt."

Les maladies rares feront-elles exploser nos systèmes de santé ?- Liberation, May 31, 2018
"Selon le cabinet Evaluate Pharma, les ventes mondiales de traitements pour ces maladies oubliées seront passées de 20 milliards à 200 milliards de dollars entre 2000 et 2022."

5 Reasons This Legendary Dividend Blue Chip Could Crush The Market Over The Next Decade- Seeking Alpha, May 31, 2018
"That includes prostate cancer drug Erleada which is expected to generate $1.6 billion in annual sales by 2022 according to analyst firm EvaluatePharma."

Half of orphan drug sales to come from cancer, Evaluate finds - Biopharma Dive, May 30, 2018
"EvaluatePharma predicts that, among the top 10 drugmakers in the space at 2024, 60% of their orphan drug sales will come from oncology therapies and only one company won't have any sales from oncology orphan drug indications."

Are Orphan Drugs Losing their Luster?- Rare Daily, May 30, 2018
"EvaluatePharma’s annual Orphan Drug Report forecasts that orphan drug sales will climb 11 percent a year through 2024, reaching $262 billion."

Orphan drugs to grow twice as fast as rest of the industry: report- MM&M, May 25, 2018
"Orphan drug sales are set to grow 11% each year between now and 2024, compared with 6.4% growth for the overall pharma market in the same period, according to a report from EvaluatePharma."

Deutsche Pharma-Konzerne außen vor- Boerse, May 25, 2018
"Die Analysten des Beratungsunternehmens EvaluatePharma gehen davon aus, dass die Konzerne alleine in den Jahren 2018/2019 fast 40 Milliarden Umsatz einbüßen."

Sanofi calls for Zynquista to be marketed for diabetes in the US- Les Echos investir, May 22, 2018
"The Zynquista may be put on the market next year and its turnover could reach $ 1.3 billion in 2022, according to a consensus of analysts' forecasts established by EvaluatePharma, in a context of interest. of the medical community for SGLT2 inhibitors, which offer a new therapeutic option in diabetes."

FDA starts review of Sanofi’s oral type 1 diabetes drug- PMLive, May 22, 2018
"While not expected to scale those heights, sotagliflozin could be a valuable addition to the franchise, with EvaluatePharma estimating it could have sales of almost $1.2bn by 2022 if it reaches the market on schedule."

Amgen, Novartis Set to Launch Migraine Drug Aimovig Next Week after FDA Approval - Genetic Engineering & Biotechnology News, May 18, 2018
"Aimovig has been projected by Evaluate Pharma to generate about $475 million in sales by 2022."

10 Major Drugs Losing Patent Protections in 2018- Pharmaceutical Manufacturing, May 16, 2018
"According to estimates by EvaluatePharma, a whopping $215 billion in sales for medications could be lost from patent expirations between 2015-2020 and $31 billion are at risk in 2018 alone."

Recon: Novartis Lawyer Exits Over Cohen Payments - Regulatory Focus, May 16, 2018
" ... Lilly's cluster buster puts Amgen in a fluster (EP Vantage); Asco preview – lung cancer battle takes centre stage (EP Vantage); Merck, Eiger expand ... "

Recon: Trump Admin Cracks Down on Drug Price Hikes - Regulatory Focus, May 14, 2018
"Vantage view – how biopharma is meeting the next payer challenge (EP Vantage); Why does Wall Street love Trump's ineffective drug-price plan?"

Medtech: five trends for the future - Pharmaphorum, May 14, 2018
"The medical devices and technology market will reach $500 billion in sales in just three years, according to EvaluateMedTech."

Look back at pharma news in week to May 11- Pharma Letter, May 13, 2018
" ... big pharma offering a billion-dollar payday for developers of cytokine cancer drugs, commented EP Vantage, the editorial arm of the Evaluate group."

Why Pharma Strategic Planning Reduces Productivity And How To Fix It - Forbes, May 11, 2018
"Here is a chart showing drug sales for 2012, as reported by EvaluatePharma."

The 2018 market for pharma cold chain logistics is $15 billion - Pharmaceutical Commerce, May 8, 2018
"That fraction of approved drugs is then compared to measures of overall pharma sales (from organizations like IQVIA and Evaluate Pharma), and overall pharma logistics spend and volumes."

The Acquisition record pour une entreprise japonaise - Le Monde, May 8, 2018
"Longtemps délaissé, ce marché fait désormais figure d’eldorado pour les industriels dont la recherche patine : les ventes de médicaments orphelins devraient atteindre 209 milliards en 2022 contre 123 milliards en 2017, selon Evaluate Pharma, avec un taux de croissance annuelle supérieur à 11 %, contre 6 % pour les médicaments classiques."

Look back at pharma news in week to May 4 - Pharma Letter, May 6, 2018
"With Novartis drug Kymriah's US lymphoma approval in the bag as of Tuesday, the CAR-T market has its first head-to-head battle, says EP Vantage, the editorial arm of the Evaluate group."

Achaogen slides after ‘yes and no’ adcomm verdict on plazomicin - FierceBiotech, May 3, 2018
"Analysts at Leerink and Stifel both suggested plazomicin could still be used off-label in this indication even if the FDA turns it down, according to an EP Vantage report."

April 2018

Look back at pharma news in week to April 20 - Pharma Letter, April 22, 2018
"Commenting on last Thursday’s development, EP Vantage, the editorial arm of the Evaluate group, said Takeda might have been rebuffed so far, but confirmation of three firm bids for Shire shows that the Japanese company is very serious."

Look back at pharma news in week to April 6 - Pharma Letter, April 8, 2018
"The deal Boehringer Ingelheim signed with OSE Immunotherapeutics last week will not come close to challenging biotech’s most lucrative transactions, but it could breathe new life into an immuno-oncology strategy that had recently been fizzling out, according to EP Vantage, the editorial arm of the Evaluate group."

Phase III combo trial failure wipes $4 billion off Incyte’s value - Pharma Letter, April 7, 2018
"The Echo-301 trial of Incyte’s epacadostat plus Keytruda in first-line melanoma presented biotech investors with the biggest binary outcome event of 2018, commented EP Vantage, the editorial arm of the Evaluate group."

Keytruda/epacadostat combo crashes in PhIII melanoma study, raising questions about the future of IDO for Incyte - Endpoints, April 6, 2018
"Epacadostat was number 3 on Evaluate Pharma’s top 10 list of 2018 launches, with close to $2 billion in projected peak sales estimates."

March 2018

Sosei see Teva pipeline cull as an opportunity- PharmaPhorum, March 30, 2018
Data source: Evaluate Pharma: Top ten drugs by sales globally, with monoclonal antibodies highlighted. Top ten companies by sales of prescription and over-the-counter drugs.

The time has come for significant changes in the pharmaceutical industry- The Republic, March 30, 2018
"Oncology drugs have the largest share in the global pharmaceutical market. According to Evaluate Pharma, in 2016 they were responsible for 12 percent. market and at the same time it is to be the second fastest growing therapeutic area in 2016-2022..."

Sanofi Diabetes Pills 'sotagliflozin' EU Screening- NewsMP, March 30, 2018
"EvaluatePharma, a drug-market research firm, predicts that sales of products will reach $ 1.16 billion in 2022."

The Top drugs and companies by sales in 2017- Nature, March 28, 2018
Data source: Evaluate Pharma: Top ten drugs by sales globally, with monoclonal antibodies highlighted. Top ten companies by sales of prescription and over-the-counter drugs.

The 10 Biotech Venture Capital Firms in Europe to Watch in 2018 - labiotech, March 26, 2018
"We have invested in all economic crises or stock market downturns in the last 15 years and always managed to distribute money to our LPs,” EdRip partner Raphaël Wisniewski recently told EP Vantage."

AbbVie sweeps back-to-back PhIIIs for uterine fibroid patients, adding to elagolix’s blockbuster rep - Endpoints, March 13, 2018
"Evaluate Pharma pegged this drug as one of the top 10 likely rollouts for 2018, with $1.2 billion in peak sales."

AbbVie’s Elagolix Dazzles in Phase III Trial - Pharma Live, March 13, 2018
"Evaluate Pharma has projected that elagolix could hit $1.2 billion in peak sales."

Big Pharma's winners and losers last year? AbbVie and AstraZeneca up, GSK down - FiercePharma, March 15, 2018
"The biopharma industry faced plenty of uncertainty in 2017, but for most companies, the year delivered a rebound from stagnation, EP Vantage reports."

 February 2018

Niche Drugs Market Looks Set to Balloon - Financial Times, February 28, 2018
" EvaluatePharma, a research group, estimates total orphan drug sales will rise from $127bn for 2017 to $217bn in 2022, while their share of the revenue from all prescription medicines will increase from 16 per cent to 21 per cent."

FDA refuses to file Celgene’s NDA for new MS drug candidate - Pharma Letter, February 28, 2018
"According to Evaluate Pharma, sales of ozanimod could reach more than $2 million by 2020 in MS alone, and if it also comes through in the Crohn’s disease and ulcerative colitis indications, the combined peak sales figure might be $5 billion."

Medtech faces 2018 challenges, FDA a bright spot - MassDevice, February 28, 2018
"According to the Pharma, Biotech and Medtech 2017 in Review report from EP Vantage, the editorial arm of life science market researcher Evaluate, the trends of 2017 augur worst for smaller medtech enterprises."

FDA turns down Celgene’s filing for multiple sclerosis drug - PM Live, February 28, 2018
"A recent EvaluatePharma reported suggested the drug could achieve sales of around $1.8bn in 2022."

Eli Lilly Korea earned ₩12 billion from Trulicity sales in 2017 - Korea Biomedical Review, February 27, 2018
"Analyst firm Evaluate Pharma estimated Trulicity would become the second highest sales in the market for diabetic medicines by 2022."

FDA backs earlier use of Lilly’s breast cancer drug Verzenio - PM Live, February 28, 2018
"The pharma company reckons Verzenio has the potential to be a best-in-class drug that can mount a strong challenge to Ibrance (palbociclib - which grew 46% to $3.1bn last year and is predicted to become a $6bn product at peak by EvaluatePharma - as well as Novartis’ second-to-market CDK4/6 inhibitor Kisqali (ribociclib))."

What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two - FierceBiotech, February 26, 2018
"They’re still among the top 10, according to EP Vantage, citing EvaluatePharma data."

Look back at pharma news in week to Feb 23 - Pharma Letter, February 25, 2018
"Friday’s European approval for Ultragenyx’ burosumab marks the first green light for this rare disease drug and sets the stage for a more important event: a US Food and Drug Administration decision, due in April, that should bring with it the company’s second priority review voucher, opines EP Vantage, the editorial arm of the Evaluate group."

Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event - Endpoints, February 12, 2018
"The news was first reported by EP Vantage writer Jacob Plieth, who noticed chatter about the dosing halt on Facebook citing issues with rhabdomyolysis side effects - a breakdown of muscle tissue that triggers severe pain."

How Huge is the Latest HIV Drug Approval for Gilead? - Motley Fool, February 12, 2018
"Market research firm EvaluatePharma thinks that Biktarvy will be the biggest new drug launch of 2018, ahead of some highly promising other new drugs on the way."

Sarepta slips on UK golodirsen study hall but expects to get back on track - FierceBiotech, February 9, 2018
"EP Vantage first reported the halt in the study, dubbed Essence, citing a Facebook post from the parent of a child involved in the study: " My son was due his biopsy and first dose of 45 skip [in] Essence last week. They have temporarily stopped dosing in the UK...I understand due to rhabdomyolysis side effects," the parent wrote."

J&J files next generation prostate cancer drug in Europe - Pharmaphorum, February 9, 2018
"A recent estimate from analysts EP Vantage forecast the drug could earn $1.4 billion by 2022."

GlaxoSmithKlines's upward trajectory faces a £750M knock with Advair copies. What can fill the gap? - FiercePharma, February 6, 2018
"Evaluate Pharma figures that apalutamide can bring in $1.6 billion in 2022. Xtandi—which delivered a combined $2.59 billion for Astellas and Pfizer last year—is set to grow to $4.71 billion in 2022, EP has said, putting it among the top 15 best-selling cancer drugs that year, according to data compiled for FiercePharma last year."

Prostate cancer shake-up looms with new data from Pfizer, Astellas and Johnson & Johnson - FiercePharma, February 7, 2018
"Over its lifetime, Advair's lifetime sales haul totted up to $101 billion as of last fall, according to EvaluatePharma research, topped only by AbbVie's Humira and Pfizer's Lipitor."

Pfizer vs J&J: Researchers are duking it out for the championship title in nonmetatastic prostate cancer - Endpoints, February 5, 2018
"Evaluate Pharma has pegged 2022 sales at $1.6 billion for apalutamide, flagging some of the zeal that analysts have for this drug."

3 Top Obesity-Drug Stocks to Consider Buying Now - Motley Fool, February 5, 2018
"Market research team EvaluatePharma ranks aducanumab as the most valuable pipeline asset in the world right now."

Look back at news in week to Feb 2 - Pharma Letter, February 5, 2018
"Today Sanofi secured its place in this club, showing how seriously its chief executive Olivier Brandicourt, views its poor pipeline and plummeting Lantus sales, according to EP Vantage, the editorial arm of the Evaluate group."

3 Top Orphan-Drug Stocks to Buy Now - Motley Fool, February 3, 2018
"It's not a big moneymaker for AbbVie yet, but EvaluatePharma projects the drug could generate over $1.8 billion in sales by 2022."

Top product sales forecasts for 2018 - Nature, February 1, 2018

 January 2018

Look back at pharma news in week to Jan 26 - The Pharma Letter, January 28, 2018
"In the end, Juno Therapeutics only paid a small penalty for its setbacks and for likely ending up the third CAR-T company to reach the market, commented EP Vantage..."

FTSE 350: Big pharma braced for a rocky year - Investors Chronicle, January 25, 2018
"In June, things became much worse when Evaluate Pharma trimmed its guidance for drugs sales growth for the first time ever."

The first complete AIDS single monotherapy listed on the market has been a major breakthroug - Sina, January 23, 2018
"According to Evaluate Pharma's forecast in the report "World Preview 2017, Outlook to 2022", based on the HIV combination, Gilead will continue to lead the antivirus market in 2022, but given Triumeq higher market expectation, % Of annual growth rate, reaching 5,376 million US dollars by 2022, 12.6% market share."

Sanofi to Acquire Bioverativ for $11.6 Billion - Financial Times, January 22, 2018
"Source: WFH 2016, MRB 2016, ATHN 2016, Evaluate Pharma"

Look back at pharma news in week to Jan 19 - The Pharma Letter, January 21, 2018
"But as Eiger Biopharma discovered, it is no guarantee of success, commented EP Vantage, the editorial arm of the Evaluate group."

Le previsioni 2018 per il settore pharma e biotech - Notizaro Chmco Farmaceutico, January 19, 2018
"Ma come sempre non è il caso di riposarsi sugli allori, e il nuovo report “EP Vantage 2018 Preview” disegna anche i possibili scenari alternativi che potrebbero attirare chi è alla ricerca di nuove opportunità di sviluppo per il proprio business."

Citing an 'ever-changing' market, Sanofi to lay off 400 in U.S. sales - FiercePharma, January 19, 2018
"Sanofi led all of pharma in layoffs back in 2016, a year in which it cut its global staff by 8%, according to a report from EP Vantage."

Roche: сумасшедшей прибыльности пришел конец - Российская Фармацевтика, January 18, 2018
"Если в 2016 году бестселлерная тройка из «Ритуксана»/«Мабтеры», «Авастина» и «Герцептина» обогатила «Рош» на 20,87 млрд франков, то в 2022-м, согласно прогнозам EvaluatePharma, она принесет вдвое меньше — 11,07 млрд франков."

Is Eli Lilly and Company a Buy in 2018?  - Madison.com, January 17, 2018
"Market research firm EvaluatePharma ranked Ozempic as the No. 2 top new drug of 2018."

Alteogen’s biosimilar proves similarity to Eylea  - Maeil Business News Korea, January 17, 2018
"Eylea is Regeneron’s blockbuster indicated for treatment of wet macular degeneration. Eylea sales are estimated to hit $6.5 billion this year, according to EvaluatePharma."

Posición de fuerza para el sector biofarmacéutico en este 2018 - Gaceta Medica, January 16, 2018
"Según el informe EP Vantage, el 2018 se perfila como un año incluso más prometedor que los pasados y se espera que el efectivo de inversiones sirva para reactivar el campo farmacéutico y biotecnológico."

Laboratory Gas Generators Market Trends & Opportunities with Forecast Upto 2025 - The Global Health News, January 16, 2018
"According to the market research report by EvaluatePharma, the global pharmaceutical R&D expenditure is projected to increase at a CAGR of 2.8 % from 2015 to 2022 to reach US$ 182 Bn in 2022 as against US$ 149.8 Bn in 2015."

Medizintechnikbranche profitiert von Digitalisierung - Markt&Technik, January 16, 2018
" Die Marktforscher von EvaluateMedTech prognostizieren… ...für die kommenden Jahre ein jährliches Wachstum des Weltmarktes für Medizintechnik in Höhe von rund 5 Prozent; die Marktgröße soll 2022 einen Wert von etwa 530 Mrd. USD erreichen."

Posición de fuerza para el sector biofarmacéutico en este 2018 - El Global, January 16, 2018
"Las terapias innovadoras pronto serán un éxito, según el informe EP Vantage."

Orphan medicines: the high cost of hope - Prescriber, January 15, 2018
"According to the 2017 Orphan Drug Report from EvaluatePharma, new orphan designations in Europe hit a peak of 208 in 2016; a decade earlier, in 2006, this figure was 82.3 Unsurprisingly, sales have been rising too, as the chart in Figure 2 shows."

Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017 - Genetic Engineering and Biotechnology News, January 15, 2018
"Yet, cancer represents the largest therapeutic area based on sales, racking up $93.7 billion worldwide in 2016, according to EvaluatePharma—which has projected a more than doubling of oncology therapy sales by 2022, to $192.2 billion, based on a compound annual growth rate of 12.7%"

Will 2018 Be Biogen Inc.'s Best Year Yet? - Billings Gazette, January 14, 2018
"Market research firm EvaluatePharma ranked the experimental drug as the most valuable pipeline candidate in the biopharmaceutical industry, giving it a net present value of more than $10 billion"

Which drug patents expire in 2018?  - MedCity News, January 12, 2018
"According to the EvaluatePharma World Preview 2017, Outlook to 2022 report, $194 billion in brand-name sales are at risk during the 2017-2022 period and an estimated $31 billion could be lost due to patent expirations in 2018 alone."

Bourse : les géants de la pharma qui financent le plus les biotechs et les medtechs  - La Revenu, January 11, 2018
"Le cabinet EP Vantage a établi un classement des investisseurs les plus actifs."

Rapport: Lægemidler fra danske selskaber vil dominere i 2018 - Finans, January 10, 2018
"Markedsanalyseselskabet Evaluate Group peger i en rapport om det kommende år i medicinalindustrien på, at to lægemidler fra danske selskaber vil blive de største kommercielle succeshistorier i 2018 i hver sin kategori."

Pharma Industry Outlook in 2018 - DCAT, January 10, 2018
"According to EP Vantage, the editorial arm of Evaluate Ltd., 2018 could be a strong year for M&A in the pharmaceutical industry driven by both Big Pharma’s and Big Biotech’s need to restock and strengthen pipelines."

The Health 202: This year's top 10 new drugs - The Washington Post, January 9, 2018
“The following list is from the London-based firm EvaluatePharma, and the drugs are ranked according to projected U.S. sales in 2022."

High-value unpartnered assets - biopharmadealmakers, January 8, 2018
“According to estimates from American Cancer Society, SEER, Kantar Health, IMS Institute Healthcare Informatics, Global Oncology Trend Report, and Evaluate Pharma, the total number of cancer patients worldwide is expected to reach 19 million by 2025."

Pharma-2018, tanti nuovi farmaci e fusion - adnkronos, January 8, 2018
“Questo secondo un'analisi di Ep Vantage, che prevede parecchi via libera concessi dalla Food and Drug Administration americana e un aumento delle attività di fusioni e acquisizioni, guidato dalla grande industria farmaceutica che deve 'rifornire' le pipeline e alleggerirsi dalle riforme fiscali Usa."

5 Korean pharmaceuticals jump into biobetter developing business - Korea Biomedical Review, January 8, 2018
“GC Pharma said that it is preparing for a global launch following successful trials, aiming to take 50 percent global market share, according to Evaluate Pharma."

Ligandomics: a paradigm shift in biological drug discovery - Drug Discovery Today, January 8, 2018
“With the annual JP Morgan conference— typically an event where major deals are announced — now in progress, here we highlight some of the most valuable assets that are currently unpartnered, using data provided by EvaluatePharma."

The Material of Choice for Medical Device Manufacturing - Journal of Clinical Research, January 8, 2018
"Нere are expectations for such growth, which was $370 billion in 2015 to reach $530 billion in 2022… Evaluate MedTech World Preview 2017, Outlook to 2022."

5 Biggest New Drugs of 2018 — and How You Can Profit From Their Makers - Newspaper, January 7, 2018
“Not less than 9 new medications are expected to start this 12 months which have the possible for sales to top rated $1 billion by 2022, according to market study company EvaluatePharma."

Look back at pharma news in week to Jan 5 - The Pharma Letter, January 7, 2018
"The annual JP Morgan healthcare conference is traditionally a hotbed of deal-making, and some companies are getting in on the action early – witness BioNTech's mammoth $270 million series A round, which reportedly values the German group at up to $3 billion, noted EP Vantage, the editorial arm of Evaluate..."

Teva: la crisi dels generics - La Vanguardia, January 7, 2018
"Segons les dades d’EvaluatePharma, el sector continua atomitzat, amb 20 grans firmes importants i només les dues més grans, Teva i Sandoz, amb una quota de mercat de dos digits."

Does the J.P. Morgan Healthcare Conference really set the tone for year ahead for biopharma? - MedCity, January 7, 2018
"The year in review: Twelve months later, the EP Vantage Biotech & Pharma 2016 Year in Review report hit on the same trends."

FDA Chief open to rethinking incentives on orphan drugs - salon, January 7, 2018
"The top 100 orphan drugs in the U.S. cost an average of $140,442 per patient last year, according to EvaluatePharma."

3 Small-Cap Biotech Stocks With Major Catalysts in 2018 - NASDAQ, January 6, 2018
"Market research firm EvaluatePharma estimates that plazomicin could generate sales of $313 million by 2022."

Acorda Therapeutics захотела себя продать - Mosmedpreparaty, January 6, 2018
"Если в 2016 году фампридин, продвигаемый совместно с «Байоджен» (Biogen), заработал 578 млн долларов, то в 2022-м, согласно прогнозам EvaluatePharma, оригинальная версия принесет лишь 134 млн долларов."

AbbVie's Position in the Growing Oncology Market in 2018 - Market Realist, January 5, 2018
"According to estimates from Evaluate Pharma, the global hematologic malignancy market was worth $33.0 billion in 2017 and is expected to grow to $50 billion in 2020 and $65 billion by 2025."

Another FDA 'Breakthrough' designation for Kisqali - The Pharma Letter, January 3, 2018
"EP Vantage, the editorial arm of the Evaluate group, has estimated sales of the drug $1.6 billion a year in 2022."

Novartis bags new breakthrough status for Kisqali in breast cancer - PMLive, January 3, 2018
“EvaluatePharma recently predicted that Ibrance will become a mega-blockbuster with sales of $6bn-plus in 2022, with Kisqali and Verzenio fighting for a distant second place."

Forecasting Bio/Pharma in 2018 - PharmTech.com, January 2, 2018
"Analysts at EvaluatePharma note that scientific breakthroughs improve the lives of patients and can richly reward the drug’s creators."

After disappointing 2016, new drug approvals roared back to life in 2017 - FierceBiotech, January 2, 2018
“If you look at the pace of R&D, there has probably never been a better time for a lot of science,” Ben Yeoh, senior portfolio manager at RBC Global Asset Management, said in the EP Vantage report. “We're curing cancers that we've never cured before, we've got new drugs for MS, new treatments for ..."


 Evaluate Buzz 2017

 Evaluate Buzz 2016

 Evaluate Buzz 2015

 Evaluate Buzz 2014

 Evaluate Buzz 2013

 Evaluate Buzz 2012

 Evaluate Buzz 2011